Key Trastuzumab Biosimilar Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The trastuzumab biosimilar market experienced a highly competitive environment and leading key players such as Celltrion, Biocon, and many more incorporated different competitive strategies to gain a strong hold in the market. Price aggression is followed by Biocon in the market of India that offers the market over USD 98 per dose, which is comparatively quite cheaper than the originator. Collaboration is one of the efficient competitive strategies followed by Celltrion to collaborate with Teva to boost the U.S. distribution, overcoming the PBM rebate obstacles. Reliance of India and Henlius of China followed the localized production strategy through the API self-sufficiency that helped to control the cost of production and offer an affordable range of products.
Here are some leading players in the global trastuzumab biosimilar market:
|
Company Name |
Industry Focus |
Market Share (2024) |
|
Celltrion (South Korea) |
Leading biosimilar developer |
18.4% |
|
Biocon/Mylan (India) |
Supplies Ogivri |
15.6% |
|
Pfizer (U.S.) |
Markets Trazimer: strong EU/U.S. presence. |
12.3% |
|
Amgen (U.S.) |
Kanjinti is approved in 40+ countries. |
10.4% |
|
Samsung Bioepis (South Korea) |
Ontruzant dominates EU/Asian markets. |
9.5% |
|
Dr. Reddy’s (India) |
CIPLA-Trastuzumab for low-cost markets. |
xx% |
|
Novartis/Sandoz (Switzerland) |
Ziextenz (biosimilar portfolio expansion). |
xx% |
|
Henlius (China) |
HLX02 approved in China/EU; targets APAC. |
xx% |
|
Teva (Israel) |
Partners with Celltrion for U.S. distribution. |
xx% |
|
Apotex (Canada) |
Supplies BFL-Trastuzumab in Canada/Latin America. |
xx% |
|
Stada Arzneimittel (Germany) |
Developing Lupin-Trastuzumab for India/Africa. |
xx% |
|
Lupin (India) |
Exploring anti-inflammatory SCD drugs. |
xx% |
|
Intas Pharma (India) |
Supplies Elizuma™ in emerging markets. |
xx% |
|
Shanghai CP Guojian (China) |
State-backed SCT200 biosimilar for China. |
xx% |
|
Reliance Life Sciences (India) |
ReliMAb targets cost-sensitive regions. |
xx% |
|
Hetero Drugs (India) |
Hertraz approved in 15+ countries. |
xx% |
|
Aurobindo Pharma (India) |
Developing Auro-Trastuzumab for Latin America. |
xx% |
|
JHL Biotech (Taiwan) |
Focus on APAC biosimilars; partnered with Genor Biopharma. |
xx% |
|
Probiomed (Mexico) |
Supplies ProbiHer in Latin America. |
xx% |
|
BioXpress Therapeutics (Malaysia) |
Emerging ASEAN-focused manufacturer. |
xx% |
Below are the areas covered for each company in the trastuzumab biosimilar market:
